Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients

Category Primary study
Web pagePress release - PR Newswire - Sep 20, 2021, 08:00 ET
Year 2021

This article is not included in any systematic review

This article is part of the following publication threads:
Loading references information
This article has no abstract
Epistemonikos ID: 7bf05f055e7acb55f3b9e9ff918e3efd6057214d
First added on: Oct 04, 2021